Find insight on AstraZeneca, Celltrion and more in the latest Market Talks covering the Health Care sector.

New York State Common Retirement Fund grew its position in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 7.4% during the 4th ...

AstraZeneca AZN stock has risen 8.6% in the past month, mainly due to mixed fourth-quarter results and a positive update from ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter. The ...

Learn more about whether AstraZeneca PLC or Intra-Cellular Therapies, Inc. is a better investment based on AAII's A+ Investor ...

AstraZeneca will gain full rights for roxadustat in China where it is approved to treat anaemia seen with chronic kidney ...

AstraZeneca and Daiichi Sankyo have claimed their seventh FDA approval for Enhertu, getting the go-ahead for the blockbuster drug as a second-line treatment for patients with HER2-low and HER2 ...

Just days after the FDA approved AstraZeneca and Daiichi Sankyo's Enhertu for a potentially lucrative new use, the regulatory has now cleared a diagnostic test that could help unlock the drug's ...

AstraZeneca PLC outperforms 2024 earnings estimates but faces challenges in 2025. Read why AZN patent expiries and mixed ...

Allworth Financial LP boosted its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 12.9% in the fourth quarter, ...